Nectar Lifesciences Ltd is primarily engaged in the development, manufacture and marketing of various active pharmaceutical ingredients (APIs) and finished dosage forms.
Financial Results:
Nectar Lifescience Ltd reported Revenues for Q1FY24 of ₹394.13 Crores down from ₹403.03 Crore year on year, a fall of 2.21%.
Total Expenses for Q1FY24 of ₹391.54 Crores down from ₹397.28 Crores year on year, a fall of 1.44%.
Consolidated Net Profit of ₹1.82 Crores down 53.33% from ₹3.90 Crores in the same quarter of the previous year.
The Earnings per Share is ₹0.08, down 52.94% from ₹0.17 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.